Know Your D: book authored June 2010 by Dr. Keebler,
got me to look up the topic on the web Sept 2010
pg 150 Be careful adding large amounts of vitamin D to the elderly.
- The incidence of primary hyperparathyoidism increases steadily with age.
- At age 60. 2 in 1000 women and 1 in 1,000 men have it
- By age 90 60 in 1000 women and 30 in 1,000 men - many undiagnosed
pg 138 Dr, Keebler describes the reactions of giving extra vitamin D to a 77 year old man who had undiagnosed hyperparathyoidism
- In a few weeks: become thirstier than usual, complained of feeling confused, tired, and having little appetite, extra pains
- Vitamin D level was only 27 ng/ml, but Calcium level was 12 mg/ml - whereas normal is about 10 ng/ml
Appears that should have blood test for vitamin D AND Calcium for seniors
Good Overview at Parathyroid.com - updated March 2013, has the following graphic
Yet Another Reason to Take Vitamin D WEB MD April 2000
Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications
Endocrine Reviews 22 (4): 477-501; Copyright © 2001 by The Endocrine Society; Paul Lips p.lips at vumc.nl
Department of Endocrinology, Institute for Endocrinology, Reproduction and Metabolism (EVM-Institute) and Institute for Research in Extramural Medicine (EMGO-Institute), Vrije Universiteit Medical Center, 1007 MB Amsterdam, The Netherlands
Vitamin D deficiency is common in the elderly, especially in the housebound and in geriatric patients. The establishment of strict diagnostic criteria is hampered by differences in assay methods for 25-hydroxyvitamin D. The synthesis of vitamin D3 in the skin under influence of UV light decreases with aging due to insufficient sunlight exposure, and a decreased functional capacity of the skin. The diet contains a minor part of the vitamin D requirement. Vitamin D deficiency in the elderly is less common in the United States than elsewhere due to the fortification of milk and use of supplements. Deficiency in vitamin D causes secondary hyperparathyroidism, high bone turnover, bone loss, mineralization defects, and hip and other fractures. Less certain consequences include myopathy and falls. A diet low in calcium may cause an increased turnover of vitamin D metabolites and thereby aggravate vitamin D deficiency. Prevention is feasible by UV light exposure, food fortification, and supplements. Vitamin D3 supplementation causes a decrease of the serum PTH concentration, a decrease of bone turnover, and an increase of bone mineral density. Vitamin D3 and calcium may decrease the incidence of hip and other peripheral fractures in nursing home residents. Vitamin D3 is recommended in housebound elderly, and it may be cost-effective in hip fracture prevention in selected risk groups.
Hyperparathyroidism and How It's Related to Vitamin D which follows
Hyperparathyroidism, and how it's related to Vitamin D has always been a subject of discussion among medical experts. There are two types of hyperparathyroidism: primary and secondary. Primary hyperparathyroidism is defined as a disorder in the parathyroid glands which means that there is too much secretion of parathyroid hormone (PTH) from one or more overactive, enlarged parathyroid glands. Secondary hyperparathyroidism is a disorder such as kidney failure that causes the over-activity o parathyroids. Vitamin D is needed for strong bones - quite unrelated to hyperparathyroidism. This is the main reason why hyperparathyroidism and how it's related to Vitamin D is often discussed.
If there is too much secretion of hormone from parathyroid glands, which is the main condition of primary hyperparathyroidism, there is disruption in the balance causing the blood calcium to rise. The condition of too much calcium in the blood is called hypercalcemia, which is usually used by doctors to suspect disorder in the parathyroid glands. The excessive PTH triggers the over secretion of calcium into the !bloodstream. Because of this, the bones may lose big amount of calcium but may increase in the urine, causing kidney disorder called kidney stones. PTH can also lower down the levels of blood phosphorus by increasing the phosphorus excretion in the urine. A person diagnosed with hyperparathyroidism may experience subtle symptoms, severe ones, or none at all.
Calcium and Vitamin D supplements are known as the primary treatments for hyperparathyroidism regardless of the cause, with the only difference that arises from the parathyroid hormone's inactivity due to hypomagnasemia. Since parathyroid hormone or PTH is necessary for kidneys to produce an active form of Vitamin D, patients diagnosed with hyperparathyroidism do not have enough PTH; thus, these patients could not naturally produce enough Vitamin D needed to absorb calcium in the intestines. Thus, it is easy to understand hyperparathyroidism and how it's related to Vitamin D because the two are intertwined. While its cause is unknown, doctors and medical experts use Vitamin D treat this disease at least as a supplemental treatment. Patients diagnosed with hyperparathyroidism are advised to take supplemental Vitamin D orally.
- - - - - - - - - - - -
Primary hyperparathyroidism in vicious cycle with vitamin D – safe to add - Nov 2011
Primary hyperparathyroidism - Is vitamin D supplementation safe?
Aust Fam Physician. 2011 Nov;40(11):881-4.
Rankin W. BAppSc, BMBS, PhD, MAACB, is a basic physician trainee,
Division of Medicine, Flinders Medical Centre, Bedford Park, South Australia.
Background Vitamin D deficiency is commonly seen in patients with primary hyperparathyroidism.
However, there is a widespread reluctance to provide vitamin D supplementation to this group of patients.
Objective This article examines the relationship between vitamin D deficiency and primary hyperparathyroidism and the effects of vitamin D supplementation.
Conclusion Vitamin D deficiency exacerbates primary hyperparathyroidism and vice versa.
With care, vitamin D supplementation can safely be given to selected patients with asymptomatic primary hyperparathyroidism and is suggested before deciding on medical or surgical management.
Monitoring serum calcium concentration and urinary calcium excretion is recommended while achieving vitamin D repletion.
PDF is attached at the bottom of this page
- - - - - - - - - - - - - - - -
Secondary Hyperparathyroidism reduced with paricalcitol – Nov 2011
Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Nefrologia. 2011 Nov 25;31(6):697-706. doi: 10.3265/Nefrologia.pre2011.Aug.11030.
[Article in English, Spanish]
Hervás Sánchez JG, Prados Garrido MD, Polo Moyano A, Cerezo Morales S.
Purpose: Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease. Treatment with paricalcitol, a selective vitamin D receptor (VDR) activator, has shown benefits in these patients by adequately reducing PTH levels with minimal changes in serum calcium and phosphorus.
The aim of this study was to assess the effectiveness and safety of paricalcitol in chronic renal disease patients (CKD grades 3 and 4). Methods: A study of our experience with paricalcitol was conducted in normal clinical practice in patients over 18 years diagnosed with grade 3 or 4 chronic kidney disease. Patients were periodically evaluated every 3 months. The primary endpoint of effectiveness was to obtain two consecutive decreases of (greater than or equal to) 30% in iPTH with respect to baseline values. The secondary endpoints were fulfilment of the objectives in accordance with the Spanish Society of Nephrology (SEN) and Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, as well as the relationship between the effectiveness of the treatment and different patient variables. Safety was studied by means of hypercalcaemia events.
Results: The primary study endpoint was achieved in 54.3% of patients. In addition, another 16.3% of patients had reduced iPTH by more than 30% at the 3rd visit. Therefore, 70.6% of patients reduced their iPTH levels by more than 30% in 6 months. The relationship between treatment success and both glomerular filtration rate and body mass index was significant. There were few adverse events, although hypercalcaemia was found in 5.4% of patients.
Conclusions: Treatment with paricalcitol is effective in controlling secondary hyperparathyroidism in non-dialysed patients with a wide safety margin.
WikiPedia Paricalcitol clips
Paricalcitol (marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure. Chemically, it is 19-nor-1,25-(OH)2-vitamin D2 or 19-nor-1,25-dihydroxyvitamin D2, being an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2.
Paricalcitol has been evaluated for safety in clinical studies in 454 chronic renal failure stage 5 patients. In four, placebo-controlled, double-blind, multicenter studies, discontinuation of therapy due to any adverse event occurred in 6.5% of 62 patients treated with paricalcitol, and 2.0% of 51 patients treated with placebo for 1 to 3 months.
Potential adverse events of paricalcitol injection are, in general, similar to those encountered with excessive vitamin D intake. Signs and symptoms of vitamin D intoxication associated with hypercalcemia include:
Early: Weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, and metallic taste.
Late: Anorexia, weight loss, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, elevated blood urea nitrogen, hypercholesterolemia, elevated AST and ALT, ectopic calcification, hypertension, cardiac arrhythmias, somnolence, death, and rarely, overt psychosis.|
- - - - - -
WikiPedia Secondary hyperparathyroidism introduction
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone (PTH) by the parathyroid glands in response to hypocalcemia (low blood calcium levels) and associated hypertrophy of the glands. This disorder is especially seen in patients with chronic renal failure.
WikiPedia Primary hyperparathyroidism introduction
Primary hyperparathyroidism causes hypercalcemia (elevated blood calcium levels) through the excessive secretion of parathyroid hormone (PTH), usually by an adenoma (benign tumors) of the parathyroid glands.
The prevalence of primary hyperparathyroidism has been estimated to be 3 in 1000 in the general population and as high as 21 in 1000 in postmenopausal women.
It is almost exactly three times as common in women as men.
See also VitaminDwiki
- All items in Thyroid and Parathroid category 47 items
- 2800 IU of vitamin D before and after parathyroid surgery helped a lot – RCT Jan 2014
- Hypothesis: Primary hyperparathyroidism might increase when vitamin D levels increase – Aug 2012
- Vitamin D and Primary Hyperparathyroidism – Jan 2011
- PTH does not plateau with increasing vitamin D, but does decrease with patient age – Aug 2012
- Overview Thyroid and Vitamin D
- Calcium and bone disorders in pregnancy – May 2012
- Search VitaminDWiki for hyperparathyroidism 853 items as of July 2016
- Need 40 ng of vitamin D to have proper PTH levels – May 2011
- Primary Hyperparathyroidism perfectly predicted with a Vitamin D-Based nomogram – Nov 2011
- Vitamin D3 becomes Calcidiol which becomes Calcitriol
- 50,000 IU vitamin D weekly is safe and effective for Primary Hyperparathyroidism – Jan 2013
- Graves Disease is 2.2X more likely with low vitamin D – meta-analysis May 2015
See also web
- Rockwell announced launching Calcitriol injection for secondary hyperparathyroidism May 2012
- A New, Vitamin D-Based, Multidimensional Nomogram for the Diagnosis of Primary Hyperparathyroidism July 2012
- StopThe Thyroid Madness a great webiste and book available in English, German, and Swedish
discusses vitamin D, rebels against standard TSH test, focuses on body temperature
- Hyperparathyroidism - Analysis and Market Forecasts to 2019 70 page report $6000, Nov 2012
table of contents is free, The global hyperparathyroidism therapeutics market is forecast to grow to reach $2.6 billion by 2019.
- Vitamin D supplementation in primary hyperparathyroidism, not a bad idea? Vitamin D Council, July 2013
Vitamin D Council discussion is behind a $5/month paywall
Discussion is based on Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Full free text on-line
- Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study Oct 2013
Clinical Trial using 1600 IU of vitamin D: was not enough